lorlatinib (Rx)

Dosage Forms & Strengths

tablet

• 25mg

• 100mg

Non-small Cell Lung Cancer

Indicated for metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test

100 mg PO qDay with or without food

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Dosage modifications for adverse reactions

• First dose reduction: 75 mg qDay

• Second dose reduction: 50 mg qDay

• Unable to tolerate 50 mg qDay: Permanently discontinue

Central nervous system (CNS) effects

• Grade 1: Continue at same dose or withhold dose until recovery to baseline; resume at same or reduced dose

• Grades 2 or 3: Withhold dose until Grade <1; resume at reduced dose

• Grade 4: Permanently discontinue

Grade 4 hypercholesterolemia or hypertriglyceridemia

• Withhold until recovery to Grade ≤2; resume at same dose

• If recurs, resume at reduced dose

https://reference.medscape.com/drug/lorbrena-lorlatinib-1000281

……see more….

———————

💮[MaruLabX – Science-based wellness support for everyday health. 🇺🇸]

——————-

MaruLabX Co.Ltd

Website: MaruLabx.com

#MaruLabX #HealthTips #HealthyLiving #Wellness #HealthAwareness #SelfCare #LiveWell #HolisticHealth #DailyHealth #HealthyLifestyle #HealthGoals